Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection
AssigneesThe United States of America, as represented by the Secretary, Department of Health and Human Services, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
InventorsWei Bu, Masaru Kanekiyo, Michael Gordon Joyce, Jeffrey I. Cohen
Life of this patent
Estimating the term…
Abstract
Antibodies and compositions of matter useful for the detection, diagnosis and treatment of Epstein Barr Virus (EBV) infection in mammals, and methods of using those compositions of matter for the detection, diagnosis and treatment of EBV infection are described. Also described are proteins, referred to as anti-gp350 antibody probes, and anti-gp350 B-cell probes, that maintain the epitope structure of the CR2-binding region of gp350, but do not bind CR2.
Claims16
An isolated antibody that binds Epstein Barr Virus (EBV) gp350 protein, comprising a variable heavy (VH) domain and a variable light (VL) domain, wherein:
- (a) the VH domain comprises the complementarity determining region 1 (CDR1), CDR2 and CDR3 sequences of SEQ ID NO:
- 1, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
- 6;
- (b) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
- 11, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
- (c) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
- 21, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
- 26;
- (d) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
- 31, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
- 36;
- (e) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
- 41, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
- 46;
- (f) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
- 161, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
- 166, wherein the antibody is an engineered antibody;
- (g) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
- 171, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
- 176, wherein the antibody is an engineered antibody;
- (h) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
- 181, the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
- 186, wherein the antibody is an engineered antibody;
- (i) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
- 191, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
- 196, wherein the antibody is an engineered antibody;
- (j) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
- 201, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
- 206, wherein the antibody is an engineered antibody;
- (k) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
- 211, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
- 216, wherein the antibody is an engineered antibody;
- (l) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
- 221, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
- 226, wherein the antibody is an engineered antibody;
- (m) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
- 231, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
- 236, wherein the antibody is an engineered antibody;
- (n) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
- 241, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
- 246, wherein the antibody is an engineered antibody;
- (o) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
- 251, and the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
- 256, wherein the antibody is an engineered antibody;
- (p) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
- 261, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
- 266, wherein the antibody is an engineered antibody;
- (q) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
- 271, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
- 276, wherein the antibody is an engineered antibody;
- or
- (r) the VH domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
- 281, and the VL domain comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
- 286, wherein the antibody is an engineered antibody.
Dependencies are inferred from the claim text.